Nigerian pharma tycoon Fidelis Ayebae's Fidson receives support to expand production capacity
The collaboration with NEXIM is expected to position Fidson for a stronger presence in Africa's rapidly expanding pharmaceutical market.
The collaboration with NEXIM is expected to position Fidson for a stronger presence in Africa's rapidly expanding pharmaceutical market.
This move aligns with the company’s efforts to bolster Nigeria’s self-sufficiency in healthcare, focusing on combating the country's ongoing HIV crisis.
The deal is part of a broader initiative to enhance self-sufficiency in Africa’s healthcare infrastructure, particularly in the battle against HIV.
Fidson Healthcare Plc, a leading Nigerian pharmaceutical manufacturing company led by Fidelis Ayebae, will seek shareholders’ approval to raise additional capital of up to N20 billion at its forthcoming 25th Annual General Meeting.
The surge in revenue is linked to the heightened sales of ethical products, including infusions, capsules, and tablets.
Ayebae, a banker turned accomplished industrialist, owns a 33.1-percent stake in the pharmaceutical company, which translates to 759,643,749 ordinary shares.
The recent gains solidify Ayebae’s position as one of Africa’s pharmaceutical industry magnates.
Ayebae owns an impressive 33.1-percent stake in Fidson Healthcare.
Fidson Healthcare has established itself as a leading player in the Nigerian and West African pharmaceutical industries.